US Broker Ratings

Upstream Bio, Inc. (UPB) Stock Analysis: Uncovering a 358.60% Potential Upside in the Biotech Sector

In the rapidly evolving landscape of biotechnology, Upstream Bio, Inc. (NASDAQ: UPB) is attracting considerable attention from investors, particularly due to its staggering 358.60% potential upside...

Kura Oncology, Inc. (KURA) Stock Analysis: Exploring a 294% Potential Upside in the Biotech Arena

Kura Oncology, Inc. (NASDAQ: KURA) has captured the attention of investors in the biotechnology sector, with its current stock price offering a tantalizing potential upside of..

CorMedix Inc. (CRMD) Stock Analysis: Exploring a 27.72% Upside Potential with Strong Buy Ratings

Investors looking for opportunities in the healthcare sector might find CorMedix Inc. (NASDAQ: CRMD) an intriguing prospect. This biopharmaceutical company, with a market cap of approximately..

LENZ Therapeutics, Inc. (LENZ): Biotechnology Stock with Nearly 48% Upside Potential

LENZ Therapeutics, Inc. (NASDAQ: LENZ) is making waves in the biotechnology sector, particularly for investors looking to capitalize on its promising potential upside. As a biopharmaceutical..

Butterfly Network, Inc. (BFLY) Stock Analysis: Exploring a 77% Potential Upside in the Medical Device Sector

Butterfly Network, Inc. (NYSE: BFLY) is catching the attention of investors with a compelling potential upside of 77.31%, according to recent analyst ratings. Operating in the..

STAAR Surgical Company (STAA): Investor Outlook on This Healthcare Stock’s Potential Upside

STAAR Surgical Company (NASDAQ: STAA), a prominent player in the healthcare sector specializing in medical instruments and supplies, is currently capturing investor attention for its strategic..

Evolus, Inc. (EOLS) Stock Analysis: A 142% Potential Upside Sparks Investor Interest

Evolus, Inc. (NASDAQ: EOLS) is capturing attention in the investment community with a potential upside of 142.01%, making it a stock worth a closer look. This..

Zymeworks Inc. (ZYME): Biotechnology Innovator with a 77.7% Potential Upside and Strong Buy Ratings

Zymeworks Inc. (NASDAQ: ZYME) is making waves in the biotechnology sector with its cutting-edge therapeutic platforms aimed at combating cancer and autoimmune diseases. With a promising..

OrthoPediatrics Corp. (KIDS) Stock Analysis: Exploring a 74.63% Potential Upside in the Pediatric Orthopedic Market

OrthoPediatrics Corp. (NASDAQ: KIDS) is a prominent player in the healthcare sector, specializing in the medical devices industry. With a focus on pediatric orthopedics, the company..

Spyre Therapeutics, Inc. (SYRE) Stock Analysis: Unveiling a Potential 227% Upside in the Biotech Arena

Spyre Therapeutics, Inc. (NASDAQ: SYRE) is capturing the attention of investors with its promising pipeline in the biotechnology sector, particularly focusing on innovative treatments for inflammatory..

Bicycle Therapeutics (BCYC) Stock Analysis: Unraveling a 209% Potential Upside

Bicycle Therapeutics plc (NASDAQ: BCYC) is gaining attention in the biotech investment space, primarily due to its remarkable potential upside of 209.09% as indicated by analyst..

CeriBell, Inc. (CBLL) Stock Analysis: 77% Upside Potential Ignites Investor Interest in Innovative Medical Device Pioneer

CeriBell, Inc. (CBLL), a dynamic player in the healthcare sector, is making waves in the medical device industry with its cutting-edge technology aimed at revolutionizing the..

Taysha Gene Therapies (TSHA) Stock Analysis: A Biotech Gem with 169% Potential Upside

For investors with a keen eye on the burgeoning biotech sector, Taysha Gene Therapies, Inc. (NASDAQ: TSHA) presents an intriguing opportunity. With a sharp potential upside..

Niagen Bioscience, Inc. (NAGE) Stock Analysis: Exploring a Healthcare Innovator with 22.94% Potential Upside

Niagen Bioscience, Inc. (NASDAQ: NAGE), a noteworthy player in the biotechnology sector, is gaining traction among investors for its innovative approach in the healthcare industry. With..

Xeris Biopharma Holdings, Inc. (XERS) Stock Analysis: Unpacking the 41% Potential Upside

Xeris Biopharma Holdings, Inc. (NASDAQ: XERS), a burgeoning player in the biotechnology sector, is capturing investor attention with an impressive 41.26% potential upside based on current..

Syndax Pharmaceuticals, Inc. (SNDX): Unpacking a 206% Potential Upside in Biotech

Syndax Pharmaceuticals, Inc. (NASDAQ: SNDX) stands at a pivotal moment in its corporate journey, drawing significant attention from investors due to its compelling growth potential. With..

Eton Pharmaceuticals, Inc. (ETON) Stock Analysis: Unveiling Growth Potential with a 72% Upside

Eton Pharmaceuticals, Inc. (NASDAQ: ETON) is capturing the attention of investors with its promising trajectory in the healthcare sector, specifically within the niche of drug manufacturing..

Delcath Systems, Inc. (DCTH) Stock Analysis: Exploring a 42.73% Upside Potential and Impressive Revenue Growth

In the dynamic landscape of healthcare, Delcath Systems, Inc. (DCTH) emerges as a noteworthy player in the medical devices industry, capturing investor attention with its innovative..

Intellia Therapeutics (NTLA) Stock Analysis: Exploring a 392% Potential Upside in Gene Editing

Intellia Therapeutics, Inc. (NASDAQ: NTLA), a trailblazer in the biotechnology sector, is making headlines with its promising potential for substantial returns. The company’s focus on pioneering..

RxSight, Inc. (RXST) Stock Analysis: Exploring a 42% Potential Upside in the Medical Device Sector

RxSight, Inc. (NASDAQ: RXST) is capturing significant attention in the healthcare sector, particularly within the niche of medical devices. The company, headquartered in Aliso Viejo, California,..

US Broker Ratings

US Broker Ratings

FTSE 100

Funds